DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma-Reference-Cited by-同舟云学术

DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma

Published:2001-11 Issue:9 Volume:28 Page:835-839
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Lazzarino M,Corso A,Barbarano L,Alessandrino EP,Cairoli R,Pinotti G,Ucci G,Uziel L,Rodeghiero F,Fava S,Ferrari D,Fiumanò M,Frigerio G,Isa L,Luraschi A,Montanara S,Morandi S,Perego D,Santagostino A,Savarè M,Vismara A,Morra E

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1703240.pdf

Reference22 articles.

1. Attal M, Harousseau J-L, Stoppa AM et al. Prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–97

2. Barlogie B, Jagannath S, Vesole D et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 1997 89: 789–793

3. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells J Clin Oncol 1995 13: 2547–2555

4. Scheid C, Draube A, Reiser M et al. Using at least 5 × 106/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation Bone Marrow Transplant 1999 23: 1177–1181

5. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplant for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients Blood 1995 85: 588–596

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-12

2. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07

3. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse;Current Oncology;2023-02-15

4. Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma;Hematological Oncology;2023-01-26

5. Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease;Journal of Hematology & Oncology;2022-10-23